Tag
The FELICIA phase IIb trial found that adding metformin to progestin therapy for fertility-sparing treatment in endometrial neoplasia did not improve 3-year recurrence-free survival or remission rates, though some reproductive outcomes favo
This Phase II trial demonstrates that HRS-7535, an oral small-molecule GLP-1 receptor agonist, significantly improves glycaemic control and is well-tolerated in type 2 diabetes patients inadequately controlled with metformin and SGLT2 inhib
This article explores how 11-oxygenated androgens differ by PCOS phenotypes and respond to first-line therapies, emphasizing their role in phenotyping and guiding treatment in polycystic ovary syndrome.
Researchers have identified a genetic variant in the cubilin gene (CUBN, rs1801222) that significantly increases the risk of metformin-induced vitamin B12 deficiency, with carriers of the AA genotype experiencing deficiency up to twice as f
A randomized trial of 399 adults with long COVID fatigue found that fluvoxamine significantly reduced fatigue severity at 60 and 90 days compared to placebo, while metformin showed no benefit. The study represents a potential breakthrough i
This report examines how metformin may interfere with exercise-induced improvements in vascular insulin sensitivity and aerobic fitness in adults at risk for metabolic syndrome.
A randomized clinical trial indicates that neither metformin nor ursodeoxycholic acid (UDCA) significantly improves recovery from postacute sequelae of SARS-CoV-2 (PASC) compared to placebo, highlighting the ongoing challenge of finding eff
The PERMET randomized clinical trial found that metformin did not improve the 6-minute walk distance or secondary walking outcomes in patients with peripheral artery disease without diabetes, suggesting no benefit for functional impairment
The SMARTEST trial investigates whether dapagliflozin should replace metformin as first-line therapy for early type 2 diabetes. Baseline data reveals a surprisingly high microvascular event rate, highlighting the urgent need for early organ
A multicenter randomized trial demonstrates that prophylactic metformin administration after antenatal betamethasone significantly improves maternal glycemic control and halves the risk of neonatal hypoglycemia in preterm infants, offering
The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression
A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.
A new ex vivo study shows metformin induces ROS-driven ferroptosis in acute myeloid leukemia (AML), particularly in samples with altered lipid metabolism (IDH2, FLT3 mutations). Lipidomic remodeling, CD36-mediated fatty acid uptake, and DGA
An observational MotherToBaby cohort found fewer hyperemesis gravidarum cases among women with preconception metformin exposure versus no exposure, but small numbers and wide confidence intervals limit conclusions. Nausea/vomiting frequency
A 200‑patient cross‑sectional study found metformin use tripled the odds of vitamin B12 deficiency without affecting vitamins A, B1, B6, B9, C or E, highlighting the need for targeted B12 monitoring in long‑term metformin therapy.
Comprehensive review of metformin’s role in metastatic prostate cancer with ADT highlights STAMPEDE trial’s findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlin
In the PRIME randomized phase 3 trial, metformin did not significantly reduce metabolic syndrome incidence in men starting androgen deprivation therapy, but produced modest, clinically relevant reductions in body weight, waist circumference
In the RECAM randomized phase III trial, chiglitazar (32 mg and 48 mg) as add‑on to metformin produced clinically meaningful HbA1c reductions and favorable lipid changes versus placebo over 24 weeks, with a tolerable safety profile characte
A 2025 meta-analysis of 19 RCTs (n=1657) found liraglutide combined with metformin improved glycaemia, insulin resistance, BMI, sex hormones and lipids versus metformin alone in overweight or obese women with PCOS; evidence certainty was lo
A 2025 meta-analysis of 19 RCTs (n=1657) found liraglutide combined with metformin improved glycaemia, insulin resistance, BMI, sex hormones and lipids versus metformin alone in overweight or obese women with PCOS; evidence certainty was lo
